
äºé²æ¥çš®ãåããäººã¯æªæ¥çš®è ããCOVIDã«çœ¹æ£ãããã
å èšäºã¯ãã¡ããã/Click here to read the original article.
å é±Annals of Internal Medicineèªã«çºè¡šãããç ç©¶ã«ãããšã2023幎ãã2024幎ã«ãããŠCOVID-19ããŒã¹ã¿ãŒãæ¥çš®ãã人ã¯ãæªæ¥çš®ã®äººãããCOVID-19ã«çœ¹æ£ããå¯èœæ§ãé«ãã£ãã
å é±Annals of Internal Medicineèªã«çºè¡šãããç ç©¶ã«ãããšã2023-2024幎ã«COVID-19ããŒã¹ã¿ãŒãæ¥çš®ãã人ã¯ãæªæ¥çš®ã®äººã«æ¯ã¹ãŠCOVID-19ã«çœ¹æ£ããå¯èœæ§ãé«ãã£ãã
ç±³åœé圹è»äººå¥åº·ç®¡çå±ïŒVHAïŒãéããŠè¡ããããã®ç ç©¶ã§ã¯ãVHAã®å æ¬çé»åã«ã«ãã·ã¹ãã ã®ããŒã¿ãåæããããŒã¹ã¿ãŒãåãã人ãšåããªãã£ã人ã®è»¢åž°ãæ¯èŒããã
ç ç©¶è ãã¯ãCOVID-19ææã«å¯Ÿããã¯ã¯ãã³ã®æå¹æ§ã-3.26ïŒ ã§ããããšãçºèŠãããã¯ã¯ãã³æªæ¥çš®ã®å¯Ÿç §çŸ€ãšæ¯èŒããŠãã¯ã¯ãã³æ¥çš®è ã®ææçãçµ±èšçã«ææã«é«ããããšã瀺ãããšããã®ç ç©¶ãSubstackã§æåã«å ±åããNicolas Hulscherã¯è¿°ã¹ãŠããã
ãŸããã¯ã¯ãã³ãæ¥çš®ãã人ã®å ¥é¢ãæ»äº¡ã«å¯Ÿããæå¹æ§ã¯äœããæ¥éã«äœäžããŠããããšãããã£ãã
ãæã ã®ç¥èŠã¯ãCOVID-19ã䜿çšãããŠããçŸåšã«ãããŠãããé«ãäºé²å¹æãæç¶ãããããšãã§ããæ°ããªã¯ã¯ãã³æ¥çš®æŠç¥ãéçºããåªåãå éããããã®ã§ããããšç ç©¶è ãã¯çµè«ã¥ããã
ç±³åœé£åå»è¬åå±ã¯ãæå¹æ§ã®èšåºè©Šéšãè¡ãããåã«ããŒã¹ã¿ãŒãæ¿èªãããç ç©¶è ãã¯ãæ£è ãæ¥å¢ããã§ãããåŒåžåšãŠã€ã«ã¹ã®å£ç¯ã«éã«åãããã«ããã®ãããªè©Šéšãè¡ãããªããã€ã¯ã¯ãã³ãå©çšã§ããããã«ããããšã¯äžå¯èœã§ããããšè¿°ã¹ãã
ãåŸã£ãŠãéå»ã®ææã«ããèªç¶å ç«ãšãéå»ã®ã¯ã¯ãã³æ¥çš®ãšæœåšçãªå ç«å·ã蟌ã¿ã«ããã¯ã¯ãã³èªçºå ç«ãããªãã®ã¬ãã«ã«ããéå£ã«ãããŠããŸãã¯ã¯ãã³ã®å€ç°ãé²åããŠããç¶æ³ã«ãããŠãã¯ã¯ãã³ãã©ã®çšåºŠã®è¿œå é²åŸ¡ãæäŸãããã¯äžæã§ãã£ãããšç ç©¶è ãã¯æžããŠããã
ããŒã¹ã¿ãŒãæå¹ãã©ãããçè§£ããããã«ã¯ãã¯ã¯ãã³ã®æå¹æ§ã«é¢ããå®éã®ç ç©¶ãå¿ èŠã§ããã
èè ãã¯ã900äžäººä»¥äžã®é圹è»äººã®ããŒã¿ãããVHAã®é»åã«ã«ãããŒã¿ã·ã¹ãã ãåæããã
圌ãã¯ããŒã¿ããŒã¹ããããŒã¹ã¿ãŒãæçšãã人ãç¹å®ããæçšããªãã£ãåæ§ã®äººãšè»¢åž°ãæ¯èŒããã2023幎10æ2æ¥ãã2024幎1æ3æ¥ã®éã«åéãããããŒã¿ãåæããã
èè ãã¯ã900äžä»¶ã®èšé²ã®ãã¡ãXBB.1.5ããŒã¹ã¿ãŒãæçšããçŽ59äžäººãç¹å®ãããæ¬¡ã«ç ç©¶è ãã¯ãçµ±èšçã¢ã«ãŽãªãºã ãçšããŠãã¯ã¯ãã³æªæ¥çš®ã³ããŒããããæž¬å®ããã倿°ã«åŸã£ãŠã¯ã¯ãã³æ¥çš®ã³ããŒããšæãããäžèŽãããšæãããåæ°ã®äººã ãéžãã ã
ã¯ã¯ãã³æ¥çš®ãéžæãã人ãã¡ã¯ãé«éœ¢ã§æ ¢æ§çŸæ£è ã§ãã£ããå¹³åããŠ7.1æ³é«ããæ ¢æ§è èç ã46.8ïŒ ãç³å°¿ç ã41.9ïŒ ãæ ¢æ§å¿çŸæ£ã45.1ïŒ ãæ ¢æ§å¿äžå šã65.3ïŒ ãæ ¢æ§èºçŸæ£ã38.3ïŒ ãèªç¥çã36.0ïŒ ã§ãã£ãã
ãŸãã䜵åçŸæ£ãå€ããæ»äº¡çã®ã±ã¢ã¢ã»ã¹ã¡ã³ãããŒãã¹ã³ã¢ãé«ããéå»2幎éã®ãã©ã€ããªã±ã¢åèšºåæ°ãå€ããæè¿ã®COVID-19ã¯ã¯ãã³æ¥çš®åæ°ãå€ããæè¿ã®COVID-19ææçåèšºåæ°ãå€ããéå»1幎以å ã«å ç«æå¶å€ãããæ²»çãåããå¯èœæ§ã74.1ïŒ é«ãã£ãã
ãã®æ¹æ³è«ã«ã€ããŠãChildren's Health DefenseäžçŽç ç©¶å¡ã®Karl Jablonowskiæ°ã¯ããç§ã¯éé£ããã€ããã¯ãªããããããã³ã°ããŠããªãã°ã«ãŒãã®å¥åº·çµæãå«ããããšãã§ããã°ãäºçްãªåªåã§è«æã匷åã§ããããšã¯ééããªãããšè¿°ã¹ãã
Jablonowskiæ°ã«ããã°ãèè ãã調æ»ããã°ã«ãŒãã«ãããSARS-CoV-2以å€ã®åŒåžåšææçãå ¥é¢ãæ»äº¡ã®å²åãå«ããŠããã°ããã®è«æã¯ããã«åŒ·åãããã§ããããšã®ããšã§ããã
ãèè éã¯ããã®ãããªæž¬å®å€ã¯ã¯ã¯ãã³ã®æå¹æ§ã®ç¯å²å€ã§ãããšäž»åŒµããã§ããããããããããã®æž¬å®å€ã¯ã¯ã¯ãã³ã®å®å šæ§ã®ç¯å²å ã§ããã
èè ãã¯ãå¹³å176æ¥éã®è¿œè·¡èª¿æ»ã«ãããŠãã¯ã¯ãã³ã®æå¹æ§ã¯SARS-CoV-2ææã«å¯ŸããŠ-3.26ïŒ ãSARS-CoV-2ã«ããå ¥é¢ã«å¯ŸããŠ16.64ïŒ ãSARS-CoV-2ã«ããæ»äº¡ã«å¯ŸããŠ26.61ïŒ ã§ãã£ããå ¥é¢ãšæ»äº¡ã«å¯Ÿããæå¹æ§ã¯ãæ¯èŒçäœãããã®ã§ãã£ããããæéã®çµéãšãšãã«æ¥éã«äœäžããããšèè ãã¯ææããŠããã
èè ã¯ãæå¹æ§ããã€ãã¹ã«ãªã£ãçç±ã説æããŠããªãã
Jablonowskiæ°ã«ããã°ãã¯ã¯ãã³ã®æå¹æ§ããã€ãã¹ã«è»¢ããçç±ã¯2ã€ãããšããã圌ã¯èšãïŒ
ãã¯ã¯ãã³æ¥çš®çŸ€ãããäžå¥åº·ã«ãªã£ãŠããããã¯ã¯ãã³æªæ¥çš®çŸ€ãããå¥åº·ã«ãªã£ãŠãããã®ã©ã¡ããã§ãããã¯ã¯ãã³ã«ãã£ãŠå ç«ç³»ãäœäžããææçãã¯ã¯ãã³æªæ¥çš®ã®äººããã宿䞻ã«å®çããå¯èœæ§ããããã¯ã¯ãã³æªæ¥çš®ã®æ¯èŒå¯Ÿè±¡çŸ€ã¯ææçãç²åŸããèªç¶å ç«ãç²åŸããã
ãã©ã¡ãã®ã·ããªãªã«ãããäººãæªåããããããªå»çä»å ¥ãå§ããã®ã¯éŠ¬é¹¿ããŠãããããã¯å»åŠã®å¯Ÿæ¥µã«ãããã®ã ã
ãã«ã·ã£ãŒã¯ããã®è«æã®çµæã¯ãCOVID-19ã¯ã¯ãã³ã®åŠå®çãªæå¹æ§ãå®èšŒããä»ã®5ã€ã®æ»èªä»ãç ç©¶ãè£ä»ãããã®ã ãšææããã
2024幎12æã«Cureusèªã«çºè¡šãããè«æã§ã¯ãã¯ã¯ãã³æ¥çš®è ãCOVID-19ææçãçºçãã確çã¯ãã¯ã¯ãã³æªæ¥çš®ã®äººã«æ¯ã¹ãŠ85ïŒ é«ãããšãæããã«ãªã£ãã2022幎ã«JAMA Network Openã«çºè¡šããããªãã¯ãã³ãŠã§ãŒãäžã®ã¢ã€ã¹ã©ã³ãã®äººã ã察象ãšããå¥ã®ç ç©¶ã§ã¯ã2åä»¥äžæ¥çš®ãã人ã¯1å以äžã®äººã«æ¯ã¹ãŠåææã®ç¢ºçã42ïŒ é«ãã£ãã
2022幎6æã«Nature Communicationsèªã«çºè¡šãããè«æã«ãããšããªãã¯ãã³æ ªã«å¯Ÿãããã¡ã€ã¶ãŒãšã¢ããã®æå¹æ§ã¯ã1ã3ãµæåŸã«ã¯é°æ§ã瀺ãããšãã«ã·ã£ãŒã¯æžããŠããã
2023幎ã®ã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ã®ç ç©¶ã«ããã°ãCOVID-19ææã®ãªã¹ã¯ã¯ã¯ã¯ãã³ã®æ¥çš®åæ°ãå€ãã»ã©é«ããªããç±³åœçŸç 管çäºé²ã»ã³ã¿ãŒã®ç ç©¶ã«ããã°ãã¯ã¯ãã³æ¥çš®ãåããåã©ãã¯ã¯ã¯ãã³æªæ¥çš®ã®åã©ããããææãããããçç¶ã®ããCOVID-19ãçºçããããããšãããã£ãã
ãææãä¿é²ãããããã®éºäŒå泚å°ã¯ãçŽã¡ã«äžçåžå Žããæé€ãããã¹ãæã§ãããšãã«ã·ã£ãŒã¯æžããŠããã